These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16219564)

  • 1. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Loukopoulos D
    Haematologica; 2005 Oct; 90(10):1304-5. PubMed ID: 16219564
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S; Jabbari A; Cohan N; Haghpanah S
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 8. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
    Athanassiou-Metaxa M; Kousi A; Hatzipantelis ES; Tsatra I; Ikonomou M; Perifanis V; Tsantali H
    Haematologica; 2004 Apr; 89(4):ELT07. PubMed ID: 15075120
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
    Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
    Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
    Maggio A; D'Amico G; Morabito A; Capra M; Ciaccio C; Cianciulli P; Di Gregorio F; Garozzo G; Malizia R; Magnano C; Mangiagli A; Quarta G; Rizzo M; D'Ascola DG; Rizzo A; Midiri M
    Blood Cells Mol Dis; 2002; 28(2):196-208. PubMed ID: 12064916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on "deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial".
    Saliba AN; Taher AT
    Am J Hematol; 2015 Sep; 90(9):E192-3. PubMed ID: 26044060
    [No Abstract]   [Full Text] [Related]  

  • 17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
    Anderson LJ; Wonke B; Prescott E; Holden S; Walker JM; Pennell DJ
    Lancet; 2002 Aug; 360(9332):516-20. PubMed ID: 12241655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term deferiprone chelation therapy.
    Hoffbrand VA; Wonke B
    Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.